Search

Elizabeth James,1 Holly Trautman,1 Stephen Thompson,2 Rinat Ribalov,3 Azhar Choudhry4 1Aventine Consulting LLC, Marblehead, MA, USA; 2Global Health Economics and Outcomes Research, Teva Branded Pharmaceutical Products R&D, Inc, Parsippany, NJ, USA; 3Global Health Economics and Outcomes Research, Teva Pharmaceutical Industries Ltd, Petah Tikva, Israel; 4Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc, Parsippany, NJ, USACorrespondence: Elizabeth James Tel +1 425 290 2148Email elizabeth@aventine-consulting.comBackground: Bendamustine hydrochloride (BND HCl) is indicated for first-line treatment of chronic lymphocytic leukemia (CLL) and rituximab-refractory indolent non-Hodgkin lymphoma (iNHL). There are two ready-to-dilute (RTD) formulations of BND HCl on the US market: a large-volume, long-duration infusion (BND-L) and a small-volume, short-duration infusion (BND-S). It is estimated that the shorter duration infusion could result in cost savings to infusion facilities.Objective: Estimate the one-year budget impact between BND-S and BND-L for use in the treatment of CLL and iNHL when all current BND-L utilization is replaced with BND-S, from the US infusion facility perspective.Methods: An illustrative budget impact model estimated the change in costs associated with a projected increase from 50% to 100% market share for BND-S. The model included CLL and iNHL patient populations. Budgetary costs reflected facility expenditures on drug acquisition and administration based on recommended dosing for BND-S and BND-L. The base-case model assumptions and inputs were derived from scientific literature and publicly available resources. The total budget impact was calculated annually, along with the differences in per patient cost; one-way sensitivity analyses were conducted.Results: Per-patient savings with BND-S use after the utilization shift were estimated at $2812.24 for CLL and $4769.01 for iNHL. Across both indications, the total annual in